Richard Hullihen CEO of Polarean Imagining and John Meyer on Resource Stocks
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Richard Hullihen CEO of Polarean Imagining and John Meyer on Resource Stocks
Richard Hullihen, CEO of Polarean Imaging (POLX) discusses progress in regards to patient enrolment for their phase iii clinical trial and also talks about the recent change in their share ownership.
Polarean is a clinical-stage company with a core technology that is a drug-device combination product that enables the visualisation of hyperpolarised 129Xe ("HPX") using MRI technology to help diagnose lung disease earlier, identify the type of intervention likely to benefit a patient, and to monitor the efficacy of treatment. It is currently being used at a number of research sites on a pre-FDA clearance basis to facilitate the research and evaluation of lung function, to assist in making improved disease progression assessment and to clearly visualise the effectiveness of several therapeutics which are under development.
John Meyer, Mining analyst and partner at SP Angel talks about global growth and the following companies:
BlueRock Diamonds (BRD)
Strategic Minerals (SML)
Cora Gold (CORA)
(Interview starts at 12 minutes 36 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.